featured
Addition of Bevacizumab to Gemcitabine–Docetaxel Is Not Beneficial in Metastatic Uterine Leiomyosarcoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized Phase III Trial of Gemcitabine Plus Docetaxel Plus Bevacizumab or Placebo as First-Line Treatment for Metastatic Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study
J. Clin. Oncol 2015 Feb 23;[EPub Ahead of Print], ML Hensley, A Miller, DM O'Malley, RS Mannel, K Behbakht, JN Bakkum-Gamez, H MichaelFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.